Lung cancer, breast cancer, and melanoma are the three cancers most likely to spread to the brain. Brain metastases are far more common than primary brain tumors, and they develop when cancer cells from another part of the body travel through the bloodstream, cross into the brain, and form new tumors there. Several other cancers can also reach the brain, though less frequently.
Lung Cancer: The Most Common Source
Lung cancer accounts for the largest share of brain metastases. Among people with non-small cell lung cancer (the most common type), 15% to 20% already have brain metastases at the time of diagnosis, and up to 40% develop them during the course of their disease. Roughly half of those found at diagnosis cause no symptoms at all, which is why brain imaging can sometimes reveal metastases before a person notices anything wrong.
Small-cell lung cancer has an even stronger tendency to spread to the brain. That risk is high enough that preventive radiation to the head is considered standard care for some patients, even before any brain tumors are detected. The goal is to destroy microscopic cancer deposits before they grow large enough to cause problems.
Breast Cancer: Subtype Matters
Breast cancer is the second most common source of brain metastases, but the risk varies dramatically depending on the biological subtype. Up to 50% of patients with metastatic triple-negative breast cancer or HER2-positive breast cancer will eventually develop brain metastases. These two subtypes are more aggressive in general, and they seem to have a particular ability to establish themselves in the brain. Hormone receptor-positive breast cancers, which make up the majority of cases, spread to the brain much less often.
When breast cancer does reach the brain, median survival is around 10 months, though the range is wide. Some patients live years, particularly with newer treatments that can cross into the brain more effectively.
Melanoma and Kidney Cancer
Melanoma, the most dangerous form of skin cancer, has a high rate of brain involvement relative to how common it is. Melanoma cells appear especially equipped to penetrate the brain’s defenses. They release enzymes that kill the cells lining blood vessels in the brain, physically breaking open the barrier that normally keeps foreign cells out. Median survival after brain metastases from melanoma is about 6 months.
Kidney cancer (specifically renal cell carcinoma) spreads to the brain in roughly 4% to 11% of cases. The timeline is often delayed: brain metastases typically appear one to five years after the kidney tumor is removed. In some studies, 10% of kidney cancer patients develop brain metastases within five years of surgery, making long-term monitoring important even after successful treatment of the original tumor.
Cancers That Rarely Reach the Brain
Colorectal cancer spreads to the brain in only about 1% to 3% of cases, making it uncommon compared to lung, breast, or melanoma. When it does happen, the liver and lungs are usually already involved. Prostate and head-and-neck cancers rarely produce brain metastases, though when prostate cancer does reach the brain, patients tend to have relatively longer survival (a median of 12 months) compared to other cancer types in the same situation.
Gastrointestinal cancers like pancreatic, stomach, and esophageal cancer occasionally spread to the brain, but these are among the least likely to do so. Ovarian, cervical, and endometrial cancers also reach the brain infrequently.
How Cancer Cells Get Past the Blood-Brain Barrier
The brain is protected by a tightly sealed network of blood vessels called the blood-brain barrier. Normally, this barrier blocks most substances from entering brain tissue. Cancer cells that successfully metastasize to the brain have developed ways to break through.
Some cancer cells squeeze between the cells that line brain blood vessels. They do this by releasing enzymes that dissolve the molecular “glue” holding those cells together. Breast cancer cells, for example, release tiny genetic fragments that weaken a key structural protein in the vessel wall. Melanoma cells take a more destructive approach, releasing enzymes that trigger the death of vessel-lining cells outright, creating gaps they can slip through.
Other cancer cells take a more direct route, passing straight through the lining cells rather than between them. They anchor themselves to the vessel wall using sticky surface proteins, then essentially push a channel through the cell to reach the other side. Once across, the cancer cells encounter a very different environment from their original tumor, but some are able to adapt, recruit a blood supply, and begin growing.
Symptoms of Brain Metastases
Brain metastases cause symptoms by pressing on surrounding brain tissue as they grow. The specific symptoms depend on where in the brain the tumors land, but the most common warning signs include:
- Headaches, sometimes accompanied by nausea or vomiting, often worse in the morning
- Weakness or numbness on one side of the body
- Seizures, which can be the first sign in someone who has never had them
- Cognitive changes, including worsening memory, confusion, or personality shifts
- Vision problems or difficulty speaking and understanding language
- Loss of balance or coordination
These symptoms can develop gradually or appear suddenly. About half of brain metastases found through routine screening produce no symptoms at all, which is why some cancer treatment protocols include periodic brain imaging even when patients feel fine.
How Brain Metastases Are Found
Contrast-enhanced MRI is the most sensitive tool for detecting brain metastases. It outperforms both CT scans and PET scans for this purpose. PET scans, which are widely used to find cancer elsewhere in the body, struggle in the brain because healthy brain tissue is already highly metabolically active, making it hard to distinguish a small tumor from normal surrounding tissue. MRI with a contrast agent highlights even small metastases clearly against the brain’s background.
For lung cancer patients with neurological symptoms, European guidelines recommend brain CT as an initial step, but MRI remains the preferred method for definitive assessment. In one large study, mandatory baseline brain imaging upstaged 7% of lung cancer cases, meaning it found brain involvement that changed the treatment plan.
Survival and What Affects It
Overall median survival after a brain metastasis diagnosis is about 5 months, but that number masks enormous variation depending on the original cancer type, the number of brain tumors, and what treatments are available. Breast cancer and prostate cancer patients with brain metastases have some of the longer median survivals at 10 and 12 months respectively. Small-cell lung cancer patients average about 6 months, while pancreatic cancer patients with brain involvement have a median of just 2 months.
Testicular cancer is a notable outlier. Though brain metastases from testicular cancer are rare, when they do occur, survival is significantly better than for most other cancers, with median survival not reached in population studies, meaning more than half of patients were still alive at the end of the study period.
Treatments Designed to Reach the Brain
One of the biggest challenges in treating brain metastases is the same blood-brain barrier that cancer cells had to break through. Many effective cancer drugs cannot cross it in high enough concentrations to work. This has driven the development of newer targeted therapies specifically engineered for brain penetration.
For lung cancers with certain genetic mutations, newer drugs have been designed to accumulate in brain tissue at meaningful levels. Third-generation drugs targeting specific mutations in lung cancer cells can reach the brain at concentrations roughly 16% to 75% of what circulates in the blood, a major improvement over older drugs that barely crossed at all. Some experimental agents have achieved brain concentrations that essentially match blood levels, with over 100% penetration in early clinical testing.
For HER2-positive breast cancer, newer antibody-drug combinations have shown activity against brain metastases that was not possible with earlier treatments. Immunotherapy has also opened new options for melanoma brain metastases, a situation that was historically very difficult to treat. These advances have not eliminated the problem, but they have meaningfully extended survival for certain patient groups, and the gap between treating cancer in the body versus the brain continues to narrow.